Evidence map›Paper›PMID 37378774›Full record

ArticleAdvances in experimental medicine and biology2023

Perspectives on Rapid Antigen Tests for Downstream Validation and Development of Theranostics.

G Vinaya Chandu Vidyasagar, P V Janardhan Reddy, Somesh Kumar, Sunil Kumar Polipalli, Ram Mohan Jaiswal, T C Venkateswarulu, P B Kavi Kishor, Prashanth Suravajhala, Rathnagiri Polavarapu

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
3.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

G Vinaya Chandu Vidyasagar *Genomix CARL Pvt. Ltd., Pulivendula, AP, India.
P V Janardhan Reddy *Genomix CARL Pvt. Ltd., Pulivendula, AP, India.
Somesh KumarGenome Sequencing Laboratory, Lok Nayak Hospital, Jawaharlal Nehru Marg, New Delhi, India.
Sunil Kumar PolipalliGenome Sequencing Laboratory, Lok Nayak Hospital, Jawaharlal Nehru Marg, New Delhi, India.
Ram Mohan JaiswalBlood Centre and Transplantation Immunology Lab, Mahatma Gandhi University of Medical Sciences and Technology, Jaipur, Rajasthan, India.
T C VenkateswaruluDepartment of Biotechnology, Vignan's Foundation for Science, Technology & Research, Guntur, AP, India.
P B Kavi KishorDepartment of Genetics, Osmania University, Hyderabad, India.
Prashanth SuravajhalaBioclues.org, Hyderabad, Telangana, India. prash@am.amrita.edu.
Rathnagiri PolavarapuGenomix CARL Pvt. Ltd., Pulivendula, AP, India. giri@genomixbiotech.com.
Genomix Biotech (India) · INLok Nayak Jai Prakash Narayan Hospital · INVignan's Foundation for Science, Technology & Research · INMahatma Gandhi University · INOsmania University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Point-of-care SARS-CoV-2 rapid antigen tests have proven to be useful over the years and have become more apparent to the public eye during COVID-19 pandemic due to their ease of use, rapid processing and result times, and low cost. Here, we have assessed the effectiveness and accuracy of rapid antigen tests in comparison to the standard real-time polymerase chain reaction analyses of the same samples.

Indexed as

COVID-19Precision MedicineHumansImmunologic TestsPandemicsSARS-CoV-2Sensitivity and SpecificityCOVID-19DiagnosisPolymerase chain reactionRapid antigen testSARS-CoV-2SensitivitySpecificity

Identifiers

PMID37378774
OpenAlexW4382345299

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.